Does Depakote Show Up on a Drug Test? Valproate and Workplace Panels

Depakote is a brand name for divalproex sodium, which the body converts into valproic acid (also called valproate). It is an anticonvulsant used for seizure disorders and is also prescribed as a mood stabilizer for bipolar disorder and, in some cases, for migraine prevention. It is not a controlled substance under federal scheduling, and it is not one of the drug classes that a standard pre employment or random workplace urine, oral fluid, or hair test is built to find. This article explains what panels actually screen for, why valproate does not match those targets, where people confuse it with a barbiturate, and what to do if a question ever comes up through the medical review officer (MRO) process.

What a standard workplace panel actually tests for

Federally regulated testing for safety sensitive transportation employees follows a fixed drug list under 49 CFR 40.87, which sets the analytes a certified laboratory must screen and confirm: marijuana metabolites, cocaine metabolites, phencyclidine, opioids, and amphetamines (including methamphetamine and MDMA). Many non DOT employer programs expand on that base with a 9, 10, or 12 panel configuration that adds classes such as benzodiazepines, barbiturates, methadone, propoxyphene, and sometimes methaqualone. Valproate is a branched chain carboxylic acid. It is not chemically related to cannabinoids, opioids, amphetamines, cocaine metabolites, benzodiazepines, or barbiturates, so it is not a designed target of any of those panel classes, federal or expanded.

Screening immunoassay versus confirmation

A urine cup or dip card uses an immunoassay, meaning antibodies built to bind a specific drug or drug class. A result turns presumptive positive only when a molecule in the sample binds well enough to that antibody, which usually requires a reasonably close structural resemblance to the target drug. Any nonnegative immunoassay screen on a federally regulated or most employer programs is sent for laboratory confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS), which identifies the exact molecule rather than a class resemblance. This two step design, screen then confirm, is described in the SAMHSA treatment improvement protocol chapter on urine drug testing, which walks through how immunoassay screening and definitive confirmation are used together in clinical and workplace settings. The same screen then confirm logic applies whether the specimen is urine, oral fluid, or hair, since every method still relies on an antibody step first and a chromatography or mass spectrometry step to resolve anything the antibody step flags.

There is no credible published cross reactivity between valproic acid or divalproex and the antibodies used in standard drugs of abuse immunoassays. The pharmacology reference chapter on valproic acid describes its structure and mechanism as an anticonvulsant and mood stabilizer, unrelated to the amphetamine, opioid, cannabinoid, benzodiazepine, or barbiturate families that panels target. If a lab or employer has a reason to believe an unusual interference occurred in a specific case, the confirmation step and a conversation with the certifying scientist or MRO is the way to resolve it, not a guess based on the screen alone.

The barbiturate panel confusion

Some employees ask about Depakote because they know it treats seizures and assume it sits in the same family as older seizure medications that are barbiturates, such as phenobarbital. Valproate is not a barbiturate. Barbiturates share a six member ring structure derived from barbituric acid, and a barbiturate (BAR) panel test is built around antibodies for that ring system. Valproic acid has an entirely different, open chain structure and does not share that chemistry. For readers who want the barbiturate side of this comparison, our separate article on whether phenobarbital shows up on a drug test covers how the BAR panel actually reacts to true barbiturates.

A valproate level is not a drug of abuse screen

Prescribers routinely order a blood valproate level to check whether a patient's dose is in the therapeutic range and to watch for toxicity, a practice called therapeutic drug monitoring. That blood test exists to manage the medication, not to detect drugs of abuse, and it is ordered and read by the treating clinician rather than a testing laboratory's MRO. The divalproex sodium prescribing label and the valproic acid prescribing label, both published through the National Library of Medicine's DailyMed database, describe monitoring recommendations and warnings for the medication. Neither label discusses it as a substance that interferes with workplace drug panels, because that is simply not how the medication or the test method works.

Prescription disclosure and the MRO process

Because Depakote is not a panel target, it will generally not trigger a nonnegative result in the first place. If any medication question does surface in a regulated test, federal rule still gives employees a defined path. Under 49 CFR 40.135, a laboratory confirmed positive result goes to a medical review officer before it reaches the employer. The MRO's job includes contacting the employee to ask about any legitimate medical explanation, which may include a current prescription, before a result can be reported as verified positive. Keeping a pharmacy record or the prescription itself on hand, and being ready to give the MRO the prescriber's name for verification, is the practical way to document a legitimate prescription in that review. Employers running their own programs should also confirm their SAMHSA certified laboratory and their written MRO procedure against current SAMHSA workplace guidance, since program design (panel size, confirmation thresholds, and MRO contracting) varies by employer and is not dictated by federal rule outside DOT covered positions.

Common anticonvulsants and documented panel notes

What this means for a testing program

Employers do not need a special exception for divalproex or valproic acid, and this medication is not a reason to ask a candidate or employee to disclose a prescription before testing. It only becomes relevant in a program if any nonnegative result occurs for an unrelated reason and documentation needs to be reviewed. In that situation, the employee's role is limited to answering the MRO's questions and, if asked, producing the prescription label or a pharmacy printout showing the prescriber, the medication, and the dates it was filled. The MRO's role is to decide, based on that documentation and professional judgment, whether a legitimate medical explanation accounts for the result, and that decision is separate from whatever panel or cutoff the laboratory used to screen and confirm the specimen in the first place. For employers building or refreshing a panel policy, our catalog of drug test cups lists the panel configurations available for program design, and wholesale buyers can review case quantities through the wholesale portal.

Frequently asked questions

Does Depakote show up on a standard 5 panel or 10 panel drug test?

No. Divalproex sodium and valproic acid are not analytes that standard SAMHSA or DOT panels are built to detect, and no credible cross reactivity with those immunoassays is documented.

Is Depakote a barbiturate?

No. Depakote (divalproex sodium, metabolized to valproic acid) is a branched chain carboxylic acid, structurally unrelated to barbiturates such as phenobarbital, and it does not react on a barbiturate (BAR) panel test.

Will a valproate blood level test count as a drug test?

No. A valproate level is a therapeutic drug monitoring blood test ordered by a prescriber to check dosing and watch for toxicity. It is a different test, for a different purpose, than a workplace urine or oral fluid drug screen.

What happens if a confirmed positive result comes back for an unrelated reason while someone is taking Depakote?

Under the federal MRO process, a laboratory confirmed positive is reviewed by a medical review officer before it reaches the employer, and the employee has the chance to provide a legitimate medical explanation, such as a current prescription, during that review.

Is Depakote a controlled substance?

No. Divalproex sodium and valproic acid are prescription medications and are not scheduled under federal controlled substances law, which is part of why they are not built into standard drugs of abuse panels.

Do state laws change how an employer should handle a prescription medication question during testing?

Program design and documentation practices vary by state and by employer, so any employer outside DOT covered testing should confirm its own policy and MRO procedure against current guidance rather than assume one standard rule applies everywhere.

This article is general information about drug test panel design and prescription medications. It is not legal or medical advice, and employers and employees with specific questions should consult qualified counsel, a medical review officer, or a treating clinician.